Payment overview · 2025
General Payments
$219.85
13 reported records · 7 companies
Healthcare provider profile · identity verified
John Derek Johnson, MD
Allopathic & Osteopathic Physicians|Family Medicine · JENA, LA · NPI 1619234945
Verified facts
What the public records show
CMS Open Payments records show John Derek Johnson, MD received $219.85 in general payments during 2025 across 13 reported records.
Novo Nordisk Inc accounted for 31.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Trintellix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $69.77 | 31.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.08 | 26.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.28 | 14.7% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.19 | 7.4% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $14.61 | 6.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.54 | 6.6% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.38 | 6.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $219.85 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $69.77 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $69.77 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $43.36 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $32.28 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.28 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $14.61 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 239 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 155 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 60 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 191 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
62 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
155 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
191 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
239 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 19 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 780 | 109 |
| Atorvastatin Calcium | Atorvastatin Calcium | 464 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 452 | 88 |
| Potassium Chloride | Potassium Chloride | 437 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 410 | 73 |
| Gabapentin | Gabapentin | 399 | 61 |
| Furosemide | Furosemide | 348 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 290 | 63 |
| Clopidogrel | Clopidogrel Bisulfate | 289 | 54 |
| Lisinopril | Lisinopril | 270 | 56 |
| Metformin Hcl Er | Metformin Hcl | 268 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 266 | 56 |
| Meloxicam | Meloxicam | 252 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 250 | 54 |
| Tramadol Hcl | Tramadol Hcl | 243 | 52 |
| Eliquis | Apixaban | 239 | 38 |
| Losartan Potassium | Losartan Potassium | 231 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 223 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 218 | 42 |
| Carvedilol | Carvedilol | 197 | 31 |
| Ozempic | Semaglutide | 191 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 189 | 47 |
| Glipizide | Glipizide | 188 | 25 |
| Celecoxib | Celecoxib | 179 | 35 |
| Metformin Hcl | Metformin Hcl | 176 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 175 | 28 |
| Nifedipine Er | Nifedipine | 173 | 32 |
| Montelukast Sodium | Montelukast Sodium | 172 | 28 |
| Trazodone Hcl | Trazodone Hcl | 172 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 169 | 46 |
| Omeprazole | Omeprazole | 161 | 33 |
| Jardiance | Empagliflozin | 155 | 28 |
| Valsartan | Valsartan | 150 | 33 |
| Clonazepam | Clonazepam | 140 | 19 |
| Sertraline Hcl | Sertraline Hcl | 138 | 29 |
| Allopurinol | Allopurinol | 137 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 131 | 28 |
| Alprazolam | Alprazolam | 127 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 126 | 22 |
| Mirtazapine | Mirtazapine | 118 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 112 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 106 | 21 |
| Donepezil Hcl | Donepezil Hcl | 102 | 24 |
| Simvastatin | Simvastatin | 101 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 100 | 20 |
| Finasteride | Finasteride | 100 | 20 |
| Atenolol | Atenolol | 99 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 21 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 92 | 15 |
| Lorazepam | Lorazepam | 92 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 91 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 88 | 21 |
| Warfarin Sodium | Warfarin Sodium | 82 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 24 |
| Glimepiride | Glimepiride | 77 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 14 |
| Clonidine Hcl | Clonidine Hcl | 76 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 76 | 14 |
| Buspirone Hcl | Buspirone Hcl | 73 | 12 |
| Ezetimibe | Ezetimibe | 72 | 19 |
| Torsemide | Torsemide | 71 | 13 |
| Famotidine | Famotidine | 68 | 16 |
| Levetiracetam | Levetiracetam | 68 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 68 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 67 | suppressed |
| Memantine Hcl | Memantine Hcl | 66 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 64 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 62 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 13 |
| Mounjaro | Tirzepatide | 60 | 13 |
| Temazepam | Temazepam | 60 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | suppressed |
| Pregabalin | Pregabalin | 55 | 14 |
| Glipizide Er | Glipizide | 53 | suppressed |
| Linzess | Linaclotide | 52 | suppressed |
| Myrbetriq | Mirabegron | 52 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 51 | 15 |
| Xarelto | Rivaroxaban | 51 | suppressed |
| Lovastatin | Lovastatin | 48 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 46 | suppressed |
| Prednisone | Prednisone | 46 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Verapamil Er | Verapamil Hcl | 44 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | suppressed |
| Sucralfate | Sucralfate | 42 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 41 | suppressed |
| Mupirocin | Mupirocin | 41 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Gemfibrozil | Gemfibrozil | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 11 |
| Naproxen | Naproxen | 38 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | suppressed |
| Sotalol | Sotalol Hcl | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 32 |
| Cefdinir | Cefdinir | 35 | 34 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 35 | 31 |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Trulicity | Dulaglutide | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 34 | suppressed |
| Telmisartan | Telmisartan | 34 | suppressed |
| Lansoprazole | Lansoprazole | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Rexulti | Brexpiprazole | 31 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 27 |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 27 | 25 |
| Dexlansoprazole Dr | Dexlansoprazole | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Haloperidol | Haloperidol | 25 | suppressed |
| Novolin R | Insulin Regular, Human | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | 12 |
| Oxaprozin | Oxaprozin | 23 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 19 |
| Indapamide | Indapamide | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Taztia Xt | Diltiazem Hcl | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 16 |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 18 |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 18 |
| Ondansetron Odt | Ondansetron | 19 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Trimethoprim | Trimethoprim | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 14 |
| Potassium Citrate Er | Potassium Citrate | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Nystatin | Nystatin | 14 | 13 |
| Primidone | Primidone | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Captopril | Captopril | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Ssd | Silver Sulfadiazine | 12 | suppressed |
| Sulindac | Sulindac | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $219.85 · 13 records | Novo Nordisk Inc | Azstarys, BREZTRI, CAPLYTA, ELIQUIS, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, TRINTELLIX | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error